Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|STA-8666||PEN-866|STA-12-8666||HSP90 Inhibitor 36||STA-8666 is a molecule that targets active HSP90 and is linked to the active metabolite of Camptosar (irinotecan), SN38, which may result in antitumor activity including tumor stabilization and regression (PMID: 27267850).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung small cell carcinoma||not applicable||STA-8666||Preclinical - Pdx||Actionable||In a preclinical study, small cell lung cancer cell line xenograft and patient derived xenograft (PDX) models demonstrated stabilization of tumor growth and eventual tumor regression when treated with STA-8666 (PMID: 27267850).||27267850|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03221400||Phase Ib/II||STA-8666||PEN-866 in Patients With Advanced Solid Malignancies||Recruiting|